FDA Approves Olaparib for HRR-Mutated Metastatic Castration-Resistant Prostate Cancer
Gabrielle Ientile
202019 citations
Abstract
Approximately 20% to 30% of men with metastatic castration-resistant prostate cancer have HRR gene mutation.
Topics & Concepts
OlaparibProstate cancerMedicineCancer researchOncologyInternal medicineAntiandrogensCancerPoly ADP ribose polymeraseBiologyAndrogen receptorGenePolymeraseBiochemistryPARP inhibition in cancer therapyProstate Cancer Treatment and Research